Pituitary/growth disorders
NEWS
- NEWS
- December 20, 2022
Observational data confirm that children born small for gestational age achieve the best growth outcomes if they start treatment with recombinant human growth hormone as young as possible.
- NEWS
- December 5, 2022
A multigene sequencing panel has successfully identified one or more gene variants in up to one in six children with idiopathic short stature, researchers report in Endocrine Connections.
- NEWS
- October 31, 2022
Years of treatment with recombinant human growth hormone does not increase the cumulative lifetime exposure to insulin-like growth factor-1 above the population average in children born small for gestational age, a study shows.
- NEWS
- October 31, 2022
A weekly injectable PEGylated recombinant human growth hormone gives significantly better height outcomes than no treatment in children with idiopathic short stature, shows a phase 2 trial.
In depth
- PODCAST
- December 20, 2022
Professor Martin Savage discusses the roles of clinical, endocrinological and genetic testing in the diagnosis and care of children with idiopathic short stature.
- MEETING
- November 21, 2022
REGISTRATION NOW OPEN! This is the 9th IMAGE programme, which focuses on transgender management, bone health, and the genetics and treatment of growth disorders.
- REVIEW
- October 31, 2022
Why is the growth plate the most important organ for childhood growth: how can it be investigated for clinical diagnosis?
- CASE
- April 25, 2022
A 4-year-old girl is referred to the local paediatric endocrine unit with signs of pubertal development.
